Lawrence Steinman, MD

Publication Details

  • Virtues and pitfalls of EAE for the development of therapies for multiple sclerosis TRENDS IN IMMUNOLOGY Steinman, L., Zamvil, S. S. 2005; 26 (11): 565-571

    Abstract:

    Experimental autoimmune encephalomyelitis (EAE) is a useful model for aiding the development of new treatments for MS. All therapies approved for MS ameliorate EAE. Two approved medications, glatiramer acetate and Natalizumab, were developed directly from studies in EAE. Several trials are ongoing in MS after success in EAE, including altered peptide ligands of myelin, DNA vaccines and statins. However, EAE has failed to predict the outcome of certain approaches. The reasons underlying such failures are discussed here.

    View details for DOI 10.1016/j.it.2005.08.014

    View details for Web of Science ID 000233375900004

    View details for PubMedID 16153891

Stanford Medicine Resources:

Footer Links: